

#### 4.0.03 DOC Cmte minutes

### Thyroid cancer Committee meeting 2

**Date:** 02/10/2020, 10:00-16:00

**Location:** Virtual meeting

**Minutes:** Confirmed

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>	
Richard Grünewald [RG] – Chair	(Present for notes 1 – 6)
Jeremy Davis [JD] – Topic advisor	(Present for notes 1 – 6)
John Buscombe [JB]	(Present for notes 1 – 6)
Preetha Chengot [PC]	(Present for notes 1 – 6)
Neil Cozens [NC]	(Present for notes 1 – 6)
Fiona Eatock [FE]	(Present for notes 1 – 6)
Kate Farnell [KF]	(Present for notes 1 – 6)
Steve Hyer [SH]	(Present for notes 1 – 6)
Jessica Lishak [JL]	(Present for notes 3 – 6)
Kate Newbold [KN]	(Present for notes 1 – 3)
Iain Nixon [IN]	(Present for notes 1 – 6)
Anh Tran [AT]	(Present for notes 1 – 6)

<b>In attendance:</b>		
Catrina Charlton [CC]	NICE Guideline Commissioning Manager	(Present for notes 1 – 6)
Sarah Scott [SS]	NICE Public Involvement Programme	(Present for notes 1 – 6)
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 6)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 6)
Vimal Bedia [VB]	Research Fellow	(Present for notes 1 – 6)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 6)
Lina Gulhane [LG]	Head of Information Specialists	(Present for notes 1 – 6)
Giulia Zuodar [GZ]	Project Manager	(Present for notes 1 – 6)
Ahmed Josef [AJ]	Research Fellow (observing)	(Present for notes 1 – 6)

#### 4.0.03 DOC Cmte minutes

Kevin Galbraith [KG]	Research Fellow (observing)	(Present for notes 1 – 6)
----------------------	--------------------------------	---------------------------

#### Apologies:

Sonja Hoy	GC member
-----------	-----------

#### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included prioritisation for health economic modelling and discussing protocols:

- Patient information
- Dose of radioactive iodine (RAI)
- Duration of treatment with levothyroxine
- TSH suppression versus no TSH suppression in different groups of people after thyroidectomy and RAI

#### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion Patient information, Dose of radioactive iodine (RAI), Duration of treatment with levothyroxine and TSH suppression versus no TSH suppression in different groups of people after thyroidectomy and RAI. The following declarations were received:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
John Buscombe	GC member	Co-author of Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World Journal of Nuclear Medicine. 2019 Apr;18(2):123.	Direct, non-financial, professional and personal	Non-Specific. Declare and participate.

#### 4.0.03 DOC Cmte minutes

		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476239/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476239/</a>		
John Buscombe	GC member	Buscombe J. Radioiodine and its relationship to hematologic malignancy: The confounding role of supraphysiologic thyroxine. J Clin Oncol. 2018 Jun 20;36:1884-5. Review of a study. <a href="https://ascopubs.org/doi/full/10.1200/JCO.2018.78.0395">https://ascopubs.org/doi/full/10.1200/JCO.2018.78.0395</a>	Direct, non-financial, professional and personal	Non-specific Declare and participate
Kate Farnell	GC member	Co-author of McIntyre C, Jacques T, Palazzo F, Farnell K, Tolley N. Quality of life in differentiated thyroid cancer. International Journal of Surgery. 2018 Feb 1;50:133-6.	Direct, non-financial, professional and personal	Non-specific Declare and participate
Kate Farnell	GC member	Co-author of Banach R, Bartès B, Farnell K, Rimmele H, Shey J, Singer S, Verburg FA, Luster M. Results of the Thyroid Cancer Alliance international patient/survivor survey: psychosocial/informational support needs, treatment side effects and international differences in care. Hormones. 2013 Jul 1;12(3):428-38.	Direct, non-financial, professional and personal	Non-specific Declare and participate
Kate Farnell	GC member	Co-author of Brown SR, Hall A, Buckley HL, Flanagan L, de Castro DG, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC cancer. 2019 Dec 1;19(1):582.	Direct, non-financial, professional and personal	Non-specific Declare and participate
Kate Farnell	GC member	Co-author of Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn J, John R, Nutting C, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with	Direct, non-financial, professional and personal	Specific. Declare and participate. Role as an author was to

#### 4.0.03 DOC Cmte minutes

		<p>low-dose radioiodine and thyrotropin alfa in thyroid cancer. New England Journal of Medicine. 2012 May 3;366(18):1674-85.  <a href="https://www.nejm.org/doi/full/10.1056/nejmoa1109589">https://www.nejm.org/doi/full/10.1056/nejmoa1109589</a></p> <p>Non-industry funded study supported by grants from Cancer Research UK, University College London and the University College London Hospital Comprehensive Biomedical Research Centre.</p>	I	<p>edit the draft text to make it more patient friendly for people with thyroid cancer. Not involved in the analysis of results or drafting the paper.</p>
Kate Farnell	GC member	<p>Co-author of Mallick U, Harmer C, Hackshaw A, Moss L, IoN Trial Management Group. Collaborators: Mallick U, Beare S, Evans C, Farnell K, Forsyth S, Gerrard G, Hackshaw A, Harmer C, Harrison B, Hyer S, Johnson SJ, Lemon C, Lewington V, Lunt C, Moss L, Newbold K, Nicol A, Nutting C, Reed N, Stephenson T, Wadsley J, Watkinson J, Yap B. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012 Apr;24(3):159. Trial ongoing.  <a href="http://www.isrctn.com/ISRCTN80416929">http://www.isrctn.com/ISRCTN80416929</a></p>	Direct, non-financial, professional and personal	<p>Specific. Declare and participate. Review action if study reports during guideline development.</p>
Kate Farnell	GC member	<p>Co-author of Farnell KA, Bliss RD, Mallick UK. Thyroid Cancer: One Doctor-Patient Partnership—The Newcastle Butterfly Model. In Practical Management of Thyroid Cancer 2018 (pp. 21-26). Springer, Cham</p>	Direct, non-financial, professional and personal	<p>Non-specific. Declare and participate</p>

The Chair and a senior member of the Developer's team noted that the interests

#### 4.0.03 DOC Cmte minutes

declared did not prevent the attendees from fully participating in the meeting.
<b>3. Prioritisation for health economic modelling</b>
AM presented the proposed prioritisation for health economic modelling. The GC discussed and agreed the areas proposed for modelling.
<b>4. Incorporating quality of life and patient views</b>
MP gave presentation on incorporating quality of life and patient views.
<b>5. Draft protocols</b>
MP presented draft protocols: <ul style="list-style-type: none"><li>• Patient information</li><li>• Dose of radioactive iodine (RAI)</li><li>• Duration of treatment with levothyroxine</li><li>• TSH suppression versus no TSH suppression in different groups of people after thyroidectomy and RAI</li></ul> The GC discussed and agreed the protocols.
<b>6 Any other business</b>
None.

**Date of next meeting:** 20 November 2020

**Location of next meeting:** Virtual meeting